Company Overview and News

2
Metminco expects to make announcement on proposed capital raising and acquisition by September 17

2018-09-13 proactiveinvestors.com.au - 1
Metminco Limited (LON:MNC) (ASX:MNC) has said it expects to make an announcement regarding a proposed capital raising and acquisition by Monday 17 September.
AULGF AU AGG MNC

1
Metminco expects to make announcement regarding a proposed capital raising and acquisition by 17 September

2018-09-13 proactiveinvestors.com.au
Metminco Limited (LON:MNC) (ASX:MNC) has said it expects to make an announcement regarding a proposed capital raising and acquisition by Monday 17 September.
AULGF AU AGG MNC

 
Metminco appoints exploration director in Colombia

2018-08-02 proactiveinvestors.com.au
Metminco Limited (LON:MNC ASX:MNC) has appointed Nick Winer as its director of exploration based in Medellin, Colombia.
MNC

 
Metminco announces rights issue take-up of around 72%

2018-04-20 proactiveinvestors.com.au
Mining group Metminco Limited (LON:MNC, ASX:MNC) revealed there had been take-up of around 72% of the previously announced revised rights issue.
MNC

 
Metminco announces around 72% of take-up under rights issue

2018-04-20 proactiveinvestors.com.au
Mining group Metminco Limited (LON:MNC, ASX:MNC) revealed there had been take-up of around 72% of the previously announced revised rights issue.
MNC

 
Results show Metminco with cash in the bank and in possession of a robust feasibility study for Miraflores

2018-04-03 proactiveinvestors.com.au
Metminco Limited (ASX:MNC)(LON:MNC) booked losses of A$35mln in the year to December 2017, down significantly from the A$124mln booked in the corresponding period a year earlier.
MNC

 
Results for the year to December show Metminco with cash in the bank and in possession of a robust feasibility study for Miraflores

2018-04-03 proactiveinvestors.com.au
Metminco Limited (ASX:MNC)(LON:MNC) booked losses of A$35mln in the year to December 2017, down significantly from the A$124mln booked in the corresponding period a year earlier.
MNC

 
Metminco launches bigger rights issue amid strategy shift and board changes

2018-03-23 proactiveinvestors.com.au
Metminco Limited (LON:MNC) (ASX:MNC) said it is now seeking to raise A$5.7mln through a revised rights issue as it shifts its strategy and has named a new executive chairman.
NML MNC IVR

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:MNC / METMINCO LIMITED on message board site Silicon Investor.

Century Mining Corp. (CMNCF) (Bulls Board) Century Mining Corp. (CMNCF) (Bulls Board) Century Mining Corp. (CMNCF) (Bulls Board) MNC: Monaco Coach Corporation MNC: Monaco Coach Corporation MNC: Monaco Coach Corporation
Monaco Coach ~ MNC ~ Oregonu0027s Gem ~ IBD ~ The New America Monaco Coach ~ MNC ~ Oregonu0027s Gem ~ IBD ~ The New America Monaco Coach ~ MNC ~ Oregonu0027s Gem ~ IBD ~ The New America